Toshiba Launches New ELERA™ Security Suite to Address the Industry’s Challenges Around Shrink
12.9.2023 16:05:00 EEST | Business Wire | Press release
The new ELERA ™ Security Suite from Toshiba Global Commerce Solutions empowers retailers to minimize shrink while providing consumers with enhanced checkout experiences and reduced friction. According to the latest data from the National Retail Federation, retail shrink accounted for $94.5 billion in losses in 2021 in the U.S. and continues to be a critical challenge for retailers. Available later this year, the ELERA™ Security Suite offers retailers a comprehensive solution to protect their bottom line and combat multiple forms of shrink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912900113/en/
The A.I.-powered ELERA™ Security Suite offers retailers a comprehensive solution to minimize shrink while providing consumers with enhanced checkout experiences. (Photo: Business Wire)
“In a world where every second and every cent counts, ELERA™ Security Suite is not just a tool but a strategy—turning data into decisions and losses into profits,” said Yevgeni Tsirulnik, SVP of Innovation and Incubation at Toshiba Global Commerce Solutions. “As global leaders in retail solutions, our Toshiba team and partners came together to envision and develop the A.I.-powered ELERA™ Security Suite to enhance their loss prevention measures that have a direct and positive impact on retailer profits while also improving the shopper experience.”
The ELERA™ Security Suite end-to-end solution deployed as-a-service through Toshiba’s IoT platform, fully orchestrates computer vision cameras with advanced edge A.I., to enhance profit protections and shopper experiences through:
- Monitoring consumer behavior in real-time – without servers or processing lag – via TCx® EDGEcam+ and multiple sensors, which adds enhanced security throughout the checkout area
- Responding to incidents as they occur for more impactful and timely resolutions with leading A.I.-powered computer vision
- Notifying shoppers of potential errors through proactive alerts and allowing them to correct the issue themselves – minimizing employee intervention and improving the checkout experience
- Differentiating customer’s items vs. store items they’re purchasing, improving recognition accuracy, and reducing incorrect warnings
The modular ELERA™ Security Suite system empowers retailers with versatility and opportunities to leverage the latest technology to meet their business needs. The ELERA™ Security Suite can be part of the overall ELERA™ solution, or it can be attached to other Toshiba or third-party POS systems.
“We are excited to expand our collaboration with Toshiba Global Commerce Solutions by integrating the Qualcomm® QRB5165 System-on-Chip (SoC) for IoT into Toshiba’s TCx EDGEcam+ to provide one of the best A.I. edge processing platforms in the market,” stated Art Miller, Vice President, Business Development and Head of Retail and Payments, Qualcomm Technologies, Inc. “Qualcomm QRB5165 SoC brings distributed A.I. and compute capabilities to the edge eliminating the need for expensive and power-intensive servers in the back of the store.”
This A.I.-driven solution presents benefits to both retailers and consumers across multiple touchpoints. ELERA™ Security Suite expands on the previously available ELERA™ Produce Recognition that leverages A.I. and computer vision to accurately and efficiently identify produce and eliminate the need to input produce codes at checkout manually. Retailers are already benefiting from the produce recognition innovation through improved inventory accuracy and throughput in the self-service experience enabling a more seamless checkout and positive consumer experience. Based on recent retailer data, Toshiba has found that shoppers save as much as five seconds per produce item lookup during checkout.
Retailers that invest in the ELERA™ Security Suite can see strong returns on their investment in this new technology suite through increased inventory accuracy, decreased store staff intervention, and increased adoption of their self-checkout lanes. Given Toshiba’s focus on retailers and consumer privacy, we also offer peace of mind by meeting the requirements of applicable data privacy laws, including all federal, state, regional, territorial, national, and local laws, regulations, and rules by any government agency or authority that relate to the processing or the security of personal data.
Toshiba experts will be at GroceryShop 2023 in Las Vegas from September 19-21 to showcase the ELERA™ Security Suite and a portfolio of other retail solutions that enable retailers to re-imagine, accelerate, and differentiate their shopping experiences (booth #1050).
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, Facebook, LinkedIn, Instagram, and YouTube, to learn more.
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
Qualcomm
Qualcomm is a trademark or registered trademark of Qualcomm incorporated. Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912900113/en/
Contact information
Toshiba Global Commerce Solutions
Elizabeth Romero
Director, Corporate Communications
elizabeth.romero@toshibagcs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
